[{"orgOrder":0,"company":"Avidea Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"SNP-7\/8a","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Avidea Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Avidea Technologies \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Avidea Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"VTP-800","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID 19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Barinthus Biotherapeutics \/ Vaccitech","highestDevelopmentStatusID":"1","companyTruncated":"Barinthus Biotherapeutics \/ Vaccitech"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"VTP-300","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Barinthus Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"UK Research and Innovation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Barinthus Biotherapeutics \/ UK Research and Innovation","highestDevelopmentStatusID":"4","companyTruncated":"Barinthus Biotherapeutics \/ UK Research and Innovation"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"M&G Investment Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Series B Financing","leadProduct":"ChAdOx1-HBV","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Barinthus Biotherapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.17000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Barinthus Biotherapeutics \/ M&G Investment Management","highestDevelopmentStatusID":"7","companyTruncated":"Barinthus Biotherapeutics \/ M&G Investment Management"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Arbutus Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"AB-729","moa":"Viral replication","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Barinthus Biotherapeutics \/ Arbutus Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"Barinthus Biotherapeutics \/ Arbutus Biopharma"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1-HBV","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Barinthus Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Avidea Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Acquisition","leadProduct":"SNAPvax Cancer Vaccine","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Barinthus Biotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Intravenous","sponsorNew":"Barinthus Biotherapeutics \/ Vaccitech plc","highestDevelopmentStatusID":"5","companyTruncated":"Barinthus Biotherapeutics \/ Vaccitech plc"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1-HBV","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Arbutus Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AB-729","moa":"Viral replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Barinthus Biotherapeutics \/ Vaccitech","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus Biotherapeutics \/ Vaccitech"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"ChAdOx1-HBV","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"ChAdOx1-HBV","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"ChAdOx1-HBV","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"VTP-200","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Barinthus Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"ChAdOx1-HBV","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"ChAdOx1-PCAQ","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Barinthus Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"VTP-500","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Barinthus Biotherapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Barinthus Biotherapeutics \/ CEPI","highestDevelopmentStatusID":"8","companyTruncated":"Barinthus Biotherapeutics \/ CEPI"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"VTP-200","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Barinthus Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"VTP-1000","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Barinthus Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Barinthus Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"ChAdOx1-HBV","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Barinthus Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Barinthus Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Barinthus Biotherapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Barinthus Biotherapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Barinthus lead product VTP-300 (ChAdOx1-HBV) vaccine is being evaluated in mid-stage clinical trial studies in combination with Nivolumab for treating adults with chronic hepatitis B.

                          Brand Name : VTP-300

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          October 01, 2024

                          Lead Product(s) : ChAdOx1-HBV,Nivolumab

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : VTP-1000 is an investigational, injectable antigen-specific tolerance immunotherapy that utilizes Barinthus Bio’s platform. Currently, it is being evaluated for the treatment of celiac disease.

                          Brand Name : VTP-1000

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          September 24, 2024

                          Lead Product(s) : VTP-1000

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : VTP-200 is an investigational immunotherapeutic regimen combining the ChAdOx vector and MVA vector encoding HPV antigens, evaluated for high-risk HPV infections in women.

                          Brand Name : HPV001

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          April 18, 2024

                          Lead Product(s) : VTP-200

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The partnership aims to fast-track the development of a vaccine candidate known as VTP-500 for the prevention of Middle East Respiratory Syndrome, the often fatal disease caused by the MERS coronavirus.

                          Brand Name : VTP-500

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          December 21, 2023

                          Lead Product(s) : VTP-500

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : CEPI

                          Deal Size : $34.8 million

                          Deal Type : Partnership

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : VTP-850 (ChAdOx1-PCAQ) is a next-generation prostate cancer immunotherapeutic candidate which utilizes Vaccitech’s sequential dosing approach of two proprietary nonreplicating viral vectors, ChAdOx and MVA.

                          Brand Name : VTP-850

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          June 12, 2023

                          Lead Product(s) : ChAdOx1-PCAQ,MVA-PCAQ

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : VTP-300 (MVA-HBV) is a first antigen-specific immunotherapy consists of an initial dose using the ChAdOx platform and a secondary dose using MVA encoding multiple hepatitis B antigens, including full-length surface, modified polymerase and core antigens.

                          Brand Name : VTP-300

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          March 28, 2023

                          Lead Product(s) : MVA-HBV,ChAdOx1-HBV,Nivolumab

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : VTP-200 is an investigational heterologous prime boost immunotherapy consisting of an initial dose using the ChAdOx vector and a second dose using MVA, both encoding the same HPV antigens, to elicit an immune response to HPV.

                          Brand Name : VTP-200

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          March 20, 2023

                          Lead Product(s) : VTP-200

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : VTP-300 administered as a monotherapy or in combination with a single administration of low-dose nivolumab at the time of the booster dose was administered with no treatment-related serious adverse events and infrequent transient transaminitis.

                          Brand Name : VTP-300

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          November 07, 2022

                          Lead Product(s) : MVA-HBV,ChAdOx1-HBV,Nivolumab

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : VTP-300 (also named as MVA-HBV), is a novel immunotherapy, dosed in a prime-boost regimen, whereby the immune system is primed with an adenovirus (ChAdOx) and boosted with a pox virus (MVA).

                          Brand Name : VTP-300

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          November 02, 2022

                          Lead Product(s) : MVA-HBV,ChAdOx1-HBV,Nivolumab

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Meaningful, durable reductions of Hepatitis B surface antigen (HBsAg) were seen in some patients who received VTP-300 (MVA-HBV) as either a monotherapy or in combination with a single low dose of nivolumab at the booster dose.

                          Brand Name : VTP-300

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          June 22, 2022

                          Lead Product(s) : MVA-HBV,ChAdOx1-HBV,Nivolumab

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank